摘要
T1DM与早发性心血管疾病密切相关。有些T1DM患者血糖控制未达标,需辅助疗法以助其实现达标。钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i)是独立于Ins作用机制的新型降糖药,SGLT-2i辅助治疗T1DM可改善血糖、血脂、血尿酸、尿蛋白异常,降低体重、BP等心血管事件高危因素且减少每日Ins用量。本文对SGLT-2i联合Ins辅助治疗T1DM的作用机制、心血管保护作用及安全性进行综述。
Type 1 diabetes mellitus(T1DM)is highly associated with cardiovascular disease. Most of T1DM patients did not reach the recommended blood glucose control level. Adjuvant therapy can make more patients achieve the ideal glucose level. Sodium glucose transporter 2 inhibitors(SGLT-2i)is a new type of hypoglycemic drug,which is independent of the mechanism of insulin. Many clinical trials have confirmed that SGLT-2i can improve blood glucose level,blood lipid,uric acidand urinary protein abnormalities,reduce weight,blood pressure and other cardiovascular risk factors,and can reduce the consumption of insulin.This article reviews the mechanism,cardiovascular protection and safety of SGLT-2i combined with insulin in the adjuvant treatment of T1DM.
作者
白文娟
任建功
BAI Wenjuan;REN Jiangong(The Second Clinical Medical College of Lanzhou University,Lanzhou 730000,China)
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2021年第3期229-232,共4页
Chinese Journal of Diabetes
